Research Analysts Offer Predictions for STOK FY2027 Earnings

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Research analysts at HC Wainwright increased their FY2027 EPS estimates for Stoke Therapeutics in a note issued to investors on Monday, December 15th. HC Wainwright analyst A. Ghosh now anticipates that the company will earn ($2.08) per share for the year, up from their prior forecast of ($2.41). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ FY2028 earnings at ($0.66) EPS and FY2029 earnings at $1.81 EPS.

STOK has been the subject of a number of other research reports. Canaccord Genuity Group increased their price objective on Stoke Therapeutics from $24.00 to $28.00 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Chardan Capital raised shares of Stoke Therapeutics to a “strong-buy” rating in a research report on Wednesday, November 19th. Weiss Ratings reiterated a “hold (c)” rating on shares of Stoke Therapeutics in a research note on Monday, December 8th. JPMorgan Chase & Co. boosted their price objective on shares of Stoke Therapeutics from $15.00 to $25.00 and gave the stock a “neutral” rating in a research note on Monday, November 3rd. Finally, UBS Group set a $50.00 price objective on shares of Stoke Therapeutics in a report on Monday. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Stoke Therapeutics has a consensus rating of “Buy” and a consensus target price of $34.78.

Stoke Therapeutics Stock Down 2.8%

STOK opened at $31.93 on Wednesday. Stoke Therapeutics has a 52 week low of $5.35 and a 52 week high of $38.69. The stock has a market cap of $1.82 billion, a PE ratio of 47.66 and a beta of 1.14. The business has a 50 day moving average of $30.19 and a 200-day moving average of $21.28.

Stoke Therapeutics (NASDAQ:STOK) last posted its earnings results on Tuesday, November 4th. The company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.54) by ($0.11). Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.The firm had revenue of $10.63 million for the quarter, compared to analysts’ expectations of $6.06 million.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Corient Private Wealth LLC bought a new position in shares of Stoke Therapeutics in the 2nd quarter worth $7,489,000. Wellington Management Group LLP grew its stake in Stoke Therapeutics by 438.2% in the third quarter. Wellington Management Group LLP now owns 737,753 shares of the company’s stock valued at $17,337,000 after purchasing an additional 600,687 shares during the last quarter. Polar Capital Holdings Plc raised its holdings in Stoke Therapeutics by 49.8% in the third quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock worth $31,102,000 after purchasing an additional 439,824 shares in the last quarter. Checkpoint Capital L.P. raised its holdings in Stoke Therapeutics by 139.3% in the first quarter. Checkpoint Capital L.P. now owns 730,717 shares of the company’s stock worth $4,859,000 after purchasing an additional 425,330 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in shares of Stoke Therapeutics during the first quarter valued at about $2,670,000.

Insiders Place Their Bets

In related news, insider Barry Ticho sold 3,662 shares of the business’s stock in a transaction on Friday, December 5th. The shares were sold at an average price of $31.34, for a total value of $114,767.08. Following the sale, the insider owned 19,798 shares in the company, valued at approximately $620,469.32. The trade was a 15.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, General Counsel Jonathan Allan sold 3,978 shares of the company’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $32.28, for a total transaction of $128,409.84. Following the sale, the general counsel owned 11,831 shares in the company, valued at $381,904.68. This represents a 25.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 182,166 shares of company stock worth $5,136,957. Company insiders own 9.50% of the company’s stock.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.